Huminsulin Basal (Nph) Kwikpen (Insulin Human (Rdna))

Huminsulin Basal (Nph) Kwikpen is indicated for long‑acting insulin therapy in patients with diabetes.

• Treatment of type 1 diabetes mellitus requiring basal insulin support
• Treatment of type 2 diabetes mellitus when basal insulin is needed
• Component of a basal‑bolus regimen combined with rapid‑acting insulin
• Provides stable, once‑daily or twice‑daily basal insulin levels
• Helps control hyperglycemia when diet and exercise alone are insufficient

• Insulin human (rDNA) binds to insulin receptors on muscle, adipose and hepatic cells, activating the receptor’s intrinsic tyrosine kinase activity. This triggers downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell membrane, increasing glucose uptake, and inhibiting hepatic gluconeogenesis. The NPH formulation releases insulin slowly, providing a prolonged basal effect. The resulting reduction in circulating glucose helps maintain fasting blood‑sugar levels within target ranges.

Like other insulin preparations, Huminsulin Basal (Nph) Kwikpen may be associated with adverse reactions that vary in frequency and severity.

Common

• Hypoglycemia, especially if meals are missed or activity is increased
• Mild pain, redness, or swelling at the injection site
• Lipodystrophy or localized fat accumulation with repeated use
• Transient weight gain due to fluid retention
• Peripheral edema, usually mild and reversible

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures
• Allergic reactions including anaphylaxis or urticaria
• Significant hypokalemia that may affect cardiac function
• Development of insulin antibodies causing resistance or unpredictable glucose control
• Severe local infection or cellulitis at the injection site

Before initiating therapy with Huminsulin Basal (Nph) Kwikpen, clinicians and patients should consider several safety considerations.

• Assess renal and hepatic function, as impairment may alter insulin clearance
• Perform regular self‑monitoring of blood glucose to detect hypo‑ or hyperglycemia
• Adjust the dose during acute illness, surgery, or when using systemic corticosteroids
• Avoid use in individuals with known hypersensitivity to human insulin or any excipients
• Exercise caution during pregnancy and lactation because safety data are limited
• Educate patients on proper injection technique to minimize lipohypertrophy
• Review concomitant medications that can mask hypoglycemia symptoms or affect glucose levels

Huminsulin Basal (Nph) Kwikpen can interact with other agents that alter glucose homeostasis or insulin metabolism.

Avoid

• Beta‑blockers, which may blunt typical hypoglycemia warning signs
• Thiazide diuretics, which can increase blood glucose concentrations
• Systemic corticosteroids, which raise insulin requirements and may precipitate hyperglycemia

Use with caution

• ACE inhibitors or ARBs, which may enhance insulin sensitivity and affect dosing
• Loop diuretics, due to potential alterations in potassium balance
• Non‑steroidal anti‑inflammatory drugs (NSAIDs), which can impact renal function and insulin clearance
• GLP‑1 receptor agonists, as combined therapy may increase risk of hypoglycemia
• Anticholinergic agents, which may interfere with glucose regulation